Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof

US6900233B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Karl Schoenafinger · Alzenau, DE
• Stefan Petry · Kelkheim, DE
• Gunter Muller · Frankfurt am Main, DE
• Armin Bauer · Pocking, DE
• Hubert Heuer · Frankfurt am Main, DE

Key dates

• Filing date: Feb 27, 2003
• Grant date: May 31, 2005
• Expiry date: Apr 17, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1, wherein R1, R2, R3, R4 and R5 are as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.